Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RTRX

Travere Therapeutics (RTRX) Stock Price, News & Analysis

Travere Therapeutics logo

About Travere Therapeutics Stock (NASDAQ:RTRX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$17.07
$18.13
50-Day Range
$24.25
$28.18
52-Week Range
$8.98
$24.96
Volume
1.22 million shs
Average Volume
412,277 shs
Market Capitalization
$915.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Remove Ads
Receive RTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RTRX Stock News Headlines

Travere Therapeutics price target raised to $31 from $29 at BofA
Travere Therapeutics price target raised to $44 from $42 at JPMorgan
Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
See More Headlines

RTRX Stock Analysis - Frequently Asked Questions

Travere Therapeutics, Inc. (NASDAQ:RTRX) released its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative net margin of 49.13% and a negative trailing twelve-month return on equity of 36.38%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include CVS Health (CVS), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Intercept Pharmaceuticals (ICPT).

Company Calendar

Last Earnings
11/05/2020
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RTRX
Fax
N/A
Employees
221
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-146,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$175.34 million
Price / Cash Flow
N/A
Book Value
$5.15 per share
Price / Book
3.48

Miscellaneous

Free Float
N/A
Market Cap
$915.87 million
Optionable
Not Optionable
Beta
0.67
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:RTRX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners